1. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study;Abou-Alfa;Lancet Oncol.,2020
2. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study;Abou-Alfa;Lancet Oncol.,2020
3. Agenzia Italiana del Farmaco, 2022. Pemigatinib. 〈https://www.aifa.gov.it/documents/20142/961234/Determina_377–2022_Pemazyre.pdf〉. (Accessed 21 February 2023).
4. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver Disease;Alvaro;Dig. Liver Dis.,2011
5. Associazione Italiana per lo Studio del Fegato (AISF), International Hepato-PancreatoBiliary Association (IT-IHPBA), Associazione Italiana di Oncologia Medica (AIOM), et al., 2022. Colangiocarcinoma intraepatico e perilare: linee guida per la pratica clinica. 〈https://snlg.iss.it/wp-content/uploads/2022/02/LG-100-AISF_ColangioCa.pdf〉. (Accessed 5 October 2022).